Table S1 - Immune and Viral Correlates of “Secondary Viral Control” after Treatment Interruption in Chronically HIV-1 Infected Patients

Supplementary data avidity of Gag (A) and Pol (B) specific T-cells in all patients. A: number of peptides of Gag and Pol that have reacted in the epitope mapping ELISPOT. B: Number of deduced epitopes. This number can be equal or lower than in the “peptides reacting” column, due to the overlapping nature of the peptides format used i.e. a single epitope can be present in 2 or 3 overlapping peptides. C: Number of peptides tested: if not enough cells were available to test all epitopes, only those were used that were predicted to be restricted by the patients HLA-type (Los Alamos database). D: Number of epitope-containing peptides that showed no reaction, although they reacted in the first ELISPOT. As remark for this experiment blood from a later date was used, clearly illustrating that epitope recognition varies over time. E: Number of epitope-containing peptides that provided a positive ELISPOT at each concentration. (DOC)